8-K: BullFrog AI Faces Nasdaq Delisting Threat, Issues New Equity Awards

BullFrog AI Holdings, Inc. received a Nasdaq deficiency notice for failing to meet minimum stockholder equity requirements while also approving new equity awards for executives and directors.

Summary

• BullFrog AI Holdings, Inc. (BFRG) received a notice from The Nasdaq Stock Market LLC on August 21, 2025, indicating non-compliance with the minimum stockholder equity requirement.
• The company's stockholders' equity was reported as $2,188,110, which is below the Nasdaq Capital Market's required minimum of $2,500,000.
• This deficiency does not immediately affect the trading of BFRG common stock or BFRGW tradable warrants.
• BullFrog AI has 45 calendar days to submit a plan to Nasdaq to regain compliance.
• If the plan is accepted, the company may receive an additional 180 calendar days to meet the requirement.
• The Board of Directors approved refresh equity awards for executive officers and directors on August 21, 2025.
• These awards are for compensation and retention, intended to supplement existing stock options that are 'significantly underwater.'
• The awards comprise 33% immediate vesting stock and 67% Restricted Stock Units (RSUs), with RSUs vesting 50% on September 1, 2026, and 50% on September 1, 2027.
• An aggregate of 267,842 shares underlie these awards if all RSUs fully vest.

Sentiment

Score: 3

Explanation: The company received a Nasdaq deficiency notice for failing to meet minimum equity requirements, posing a significant risk of delisting. Additionally, existing executive stock options are 'significantly underwater,' indicating poor past stock performance. While management plans to address the issue and new retention awards were issued, the core financial health and listing status are concerning.

Positives

• The Nasdaq deficiency notice has no immediate effect on the listing of the company's common stock and tradable warrants, allowing them to continue trading.
• The company intends to take all reasonable measures to regain Nasdaq compliance, including submitting a plan and potentially appealing a delisting determination.
• New equity awards were approved for executive officers and directors, serving as compensatory and retention incentives during a critical period.

Negatives

• BullFrog AI is not in compliance with Nasdaq Listing Rule 5550(b)(1), requiring a minimum of $2,500,000 in stockholders' equity, as its reported equity is $2,188,110.
• Failure to regain compliance could lead to the delisting of the company's common stock and tradable warrants from The Nasdaq Capital Market.
• Existing stock option awards for executives and directors are 'significantly underwater,' indicating a potential decline in stock price or poor performance relative to option strike prices.
• The issuance of new equity awards, while for retention, could lead to shareholder dilution if the RSUs fully vest, totaling 267,842 shares.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the Stockholder Equity Requirement.
• No assurance that the company's plan to regain compliance will be accepted by Nasdaq.
• No assurance that the company will be able to regain compliance even if its plan is accepted.
• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

Future Outlook

The company intends to take all reasonable measures to regain compliance with Nasdaq listing rules and remain listed. It is currently evaluating various options and plans to timely submit a compliance plan to Nasdaq. However, there is no assurance that the plan will be accepted or that compliance will be regained.

Management Comments

• "The Company intends to take all reasonable measures available to regain compliance with the Nasdaq listing rules and remain listed on Nasdaq."
• "The Company is currently evaluating various options to regain compliance and plans to timely submit a plan to Nasdaq to regain compliance with the Nasdaq Stockholder Equity Requirement."
• "There can, however, be no assurance that the Company’s plan will be accepted by Nasdaq or that, if it is accepted, the Company will be able to regain compliance."

Industry Context

NA

Corporate Governance

Related Party Transactions

• Refresh equity awards were approved for executive officers and directors, who are related parties, consisting of immediate vesting stock and Restricted Stock Units (RSUs) under the 2022 Equity Compensation Plan.

Stakeholder Impact

• Shareholders: Face potential dilution from new equity awards (267,842 shares if fully vested) and significant risk of delisting from Nasdaq, which could negatively impact liquidity and share price.
• Employees (Executive Officers and Directors): Benefit from new compensatory and retention equity awards, especially given that existing options are 'significantly underwater.'
• Nasdaq: The company's non-compliance impacts Nasdaq's listing standards and oversight.

Next Steps

• Submit a plan to Nasdaq within 45 calendar days to regain compliance with the Stockholder Equity Requirement.
• If the plan is accepted, work to regain compliance within an additional 180 calendar days.
• Potentially appeal a delisting determination by Nasdaq's staff to a Nasdaq hearings panel if delisted.
• Executive and director RSUs will vest 50% on September 1, 2026, and the remaining 50% on September 1, 2027.

Key Dates

Recommendation

The company faces a significant risk of delisting from Nasdaq due to non-compliance with minimum stockholder equity requirements. While management intends to regain compliance, there is no assurance of success. The fact that existing stock options are 'significantly underwater' suggests poor past performance and a lack of confidence in the current valuation. The issuance of new equity awards, while for retention, could also lead to dilution. Given the immediate delisting threat and underlying financial weakness, a cautious approach is warranted.

Keywords

BullFrog AI Holdings, BFRG, Nasdaq delisting, Stockholder equity, Listing compliance, Equity awards, Restricted Stock Units, Executive compensation, Corporate governance, Biotechnology, AI in pharma